Literature DB >> 16950218

Alterations in medial prefrontal cortical activity and plasticity in rats with disruption of cortical development.

Yukiori Goto1, Anthony A Grace.   

Abstract

BACKGROUND: Psychiatric disorders such as schizophrenia are believed to emerge from an interaction of several factors. Thus, a genetic predisposition can lead to developmental compromises that may leave the system more susceptible to deficits induced by subsequent environmental variables such as stress.
METHODS: The impact of neurodevelopmental interruption induced by exposure of rats prenatally to a compound methylazoxymethanol acetate (MAM) that disrupts neuronal proliferation was investigated using in vivo electrophysiologic recordings from the prefrontal cortex of adult rats.
RESULTS: Prenatal exposure to MAM resulted in alterations in the medial prefrontal cortex indicative of a compromise in information processing. Specifically, we observed a disruption in activity patterns consistent with deficits in neuronal synchronization and abnormal augmentation of synaptic plasticity that was more severely disrupted by stress exposure than in normal animals. Furthermore, these deficits could be reversed by manipulating the mesocortical dopamine system.
CONCLUSIONS: These results suggest that disruption of early cortical development causes impairments in medial prefrontal cortical function at adulthood that are more vulnerable to disruptive influences, despite the presence of only subtle structural alterations in the brain.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16950218     DOI: 10.1016/j.biopsych.2006.05.046

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  41 in total

Review 1.  GSK-3β activity and hyperdopamine-dependent behaviors.

Authors:  Yan-Chun Li; Wen-Jun Gao
Journal:  Neurosci Biobehav Rev       Date:  2010-08-18       Impact factor: 8.989

2.  Firing patterns of maternal rat prelimbic neurons during spontaneous contact with pups.

Authors:  Marcelo Febo
Journal:  Brain Res Bull       Date:  2012-05-27       Impact factor: 4.077

Review 3.  Disruption of cortical-limbic interaction as a substrate for comorbidity.

Authors:  A A Grace
Journal:  Neurotox Res       Date:  2006-10       Impact factor: 3.911

4.  Identifying 5 Common Psychiatric Disorders Associated Chemicals Through Integrative Analysis of Genome-Wide Association Study and Chemical-Gene Interaction Datasets.

Authors:  Shiqiang Cheng; Yan Wen; Mei Ma; Lu Zhang; Li Liu; Xin Qi; Bolun Cheng; Chujun Liang; Ping Li; Om Prakash Kafle; Feng Zhang
Journal:  Schizophr Bull       Date:  2020-04-15       Impact factor: 9.306

Review 5.  Hippocampal dysfunction and disruption of dopamine system regulation in an animal model of schizophrenia.

Authors:  Daniel J Lodge; Anthony A Grace
Journal:  Neurotox Res       Date:  2008-10       Impact factor: 3.911

6.  NMDA antagonist and antipsychotic actions in cortico-subcortical circuits.

Authors:  Lucila Kargieman; Noemí Santana; Guadalupe Mengod; Pau Celada; Francesc Artigas
Journal:  Neurotox Res       Date:  2008-10       Impact factor: 3.911

Review 7.  Electrophysiological endophenotypes in rodent models of schizophrenia and psychosis.

Authors:  Andrew M Rosen; Timothy Spellman; Joshua A Gordon
Journal:  Biol Psychiatry       Date:  2015-03-27       Impact factor: 13.382

8.  Critical role of the prefrontal cortex in the regulation of hippocampus-accumbens information flow.

Authors:  Pauline Belujon; Anthony A Grace
Journal:  J Neurosci       Date:  2008-09-24       Impact factor: 6.167

Review 9.  Neurodegenerative aspects in vulnerability to schizophrenia spectrum disorders.

Authors:  Trevor Archer; Serafino Ricci; Danilo Garcia; Max Rapp Ricciardi
Journal:  Neurotox Res       Date:  2014-05-08       Impact factor: 3.911

Review 10.  Cellular and circuit models of increased resting-state network gamma activity in schizophrenia.

Authors:  R S White; S J Siegel
Journal:  Neuroscience       Date:  2015-11-11       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.